This HTML5 document contains 109 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00344/identifier/wikipedia/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00344/identifier/pharmgkb/
foafhttp://xmlns.com/foaf/0.1/
n28http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/company/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00344/identifier/kegg-compound/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00344/identifier/pubchem-compound/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00344/identifier/pubchem-substance/
n6http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB00344/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00344/identifier/national-drug-code-directory/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n27http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n13http://www.drugs.com/cdi/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00344/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
n15http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00344/identifier/chebi/
n26http://linked.opendata.cz/resource/atc/
n25http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00344
rdf:type
n3:Drug
n3:description
Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Protriptyline may be used for the treatment of depression.
n3:dosage
n14:271B5C63-363D-11E5-9242-09173F13E4C5 n14:271B5C64-363D-11E5-9242-09173F13E4C5 n14:271B5C65-363D-11E5-9242-09173F13E4C5 n14:271B5C66-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For the treatment of depression.
n3:manufacturer
n8:271B5C45-363D-11E5-9242-09173F13E4C5 n8:271B5C46-363D-11E5-9242-09173F13E4C5 n8:271B5C43-363D-11E5-9242-09173F13E4C5 n8:271B5C44-363D-11E5-9242-09173F13E4C5 n8:271B5C47-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00344 n7:DB00344
dcterms:title
Protriptyline
adms:identifier
n10:Protriptyline n16:4805 n17:DB00344 n19:8597 n20:0555-0595-02 n21:PA451168 n22:C07408 n23:4976 n24:46505128
n3:mechanismOfAction
Protriptyline acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
n3:packager
n8:271B5C41-363D-11E5-9242-09173F13E4C5 n8:271B5C42-363D-11E5-9242-09173F13E4C5 n8:271B5C3F-363D-11E5-9242-09173F13E4C5 n8:271B5C40-363D-11E5-9242-09173F13E4C5 n8:271B5C3D-363D-11E5-9242-09173F13E4C5 n8:271B5C3E-363D-11E5-9242-09173F13E4C5 n8:271B5C3B-363D-11E5-9242-09173F13E4C5 n8:271B5C3C-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Cumulative urinary excretion during 16 days accounted for approximately 50% of the drug. The fecal route of excretion did not seem to be important.
n3:synonym
3-(5H-Dibenzo[a,D]cyclohepten-5-yl)-N-methyl-1-propanamine Protriptylinum Amimetilina N-Methyl-5H-dibenzo[a,D]cycloheptene-5-propanamine 5-(3-Methylaminopropyl)-5H-dibenzo[a,D]cycloheptene N-Methyl-5H-dibenzo[a,D]cycloheptene-5-propylamine 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene Protriptyline Protriptylin Protriptilina
n3:toxicity
Side effects include anxiety, blood disorders, confusion, decreased libido, dizziness, flushing, headache, impotence, insomnia, low blood pressure, nightmares, rapid or irregular heartbeat, rash, seizures, sensitivity to sunlight, stomach and intestinal discomfort, sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.
n27:hasConcept
n28:M0017928
foaf:page
n13:protriptyline.html n15:viv1617.shtml
n3:IUPAC-Name
n4:271B5C6B-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5C71-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5C70-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5C6D-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5C6E-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5C6F-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5C80-363D-11E5-9242-09173F13E4C5 n4:271B5C69-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5C67-363D-11E5-9242-09173F13E4C5 n4:271B5C82-363D-11E5-9242-09173F13E4C5 n4:271B5C6A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5C68-363D-11E5-9242-09173F13E4C5
n25:hasATCCode
n26:N06AA11
n3:H-Bond-Acceptor-Count
n4:271B5C77-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5C78-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5C72-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5C73-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5C75-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5C74-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5C76-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
438-60-8
n3:category
n3:containedIn
n11:271B5C61-363D-11E5-9242-09173F13E4C5 n11:271B5C62-363D-11E5-9242-09173F13E4C5 n11:271B5C5F-363D-11E5-9242-09173F13E4C5 n11:271B5C60-363D-11E5-9242-09173F13E4C5 n11:271B5C5D-363D-11E5-9242-09173F13E4C5 n11:271B5C5E-363D-11E5-9242-09173F13E4C5 n11:271B5C5B-363D-11E5-9242-09173F13E4C5 n11:271B5C5C-363D-11E5-9242-09173F13E4C5 n11:271B5C59-363D-11E5-9242-09173F13E4C5 n11:271B5C5A-363D-11E5-9242-09173F13E4C5 n11:271B5C57-363D-11E5-9242-09173F13E4C5 n11:271B5C58-363D-11E5-9242-09173F13E4C5 n11:271B5C55-363D-11E5-9242-09173F13E4C5 n11:271B5C56-363D-11E5-9242-09173F13E4C5 n11:271B5C53-363D-11E5-9242-09173F13E4C5 n11:271B5C54-363D-11E5-9242-09173F13E4C5 n11:271B5C51-363D-11E5-9242-09173F13E4C5 n11:271B5C52-363D-11E5-9242-09173F13E4C5 n11:271B5C4F-363D-11E5-9242-09173F13E4C5 n11:271B5C50-363D-11E5-9242-09173F13E4C5 n11:271B5C4D-363D-11E5-9242-09173F13E4C5 n11:271B5C4E-363D-11E5-9242-09173F13E4C5 n11:271B5C4B-363D-11E5-9242-09173F13E4C5 n11:271B5C4C-363D-11E5-9242-09173F13E4C5 n11:271B5C49-363D-11E5-9242-09173F13E4C5 n11:271B5C4A-363D-11E5-9242-09173F13E4C5 n11:271B5C48-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5C7C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5C7E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5C7F-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5C81-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5C7B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5C7A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5C7D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5C6C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5C79-363D-11E5-9242-09173F13E4C5